1
|
Assis-Mendonça GR, Campos LG, Delamain MT, de Brito ABC, Fanelli MF, Soares FA, de Souza CA, Vassallo J, Lima CSP. Association of single nucleotide variants in VEGFA and KDR with the risk and angiogenic features of diffuse large B-cell lymphoma. Leuk Lymphoma 2023; 64:2165-2177. [PMID: 37647140 DOI: 10.1080/10428194.2023.2248330] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2023] [Revised: 07/14/2023] [Accepted: 08/10/2023] [Indexed: 09/01/2023]
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype and dependent on angiogenesis (AG), whose main effectors are VEGFA and VEGFR2. Functional single nucleotide variants (SNVs) are described in VEGFA and KDR genes. However, it still unknown whether VEGFA - 2578C/A, -2489C/T, -1154G/A, -634G/C, -460C/T and KDR-604T/C, -271G/A, +1192G/A and +1719A/T SNVs act on DLBCL risk and angiogenic features. Genomic DNA from 168 DLBCL patients and 205 controls was used for SNV genotyping. Angiogenesis was immunohistochemically assessed in tumor biopsies, with reactions for VEGFA, VEGFR2, and CD34. VEGFA -1154GG genotype were associated with 1.6-fold higher DLBCL risk. KDR + 1192GG plus KDR + 1719 TT and KDR + 1192GG plus VEGFA - 2578CC combined genotypes are associated with 2.19- and 2.04-fold higher risks of DLBCL, respectively. VEGFA - 634GG or GC genotypes are associated with increased microvessel density and VEGFA levels. No relationship was observed between SNVs and cell-of-origin classification of DLBCL, but higher VEGFA and VEGFR2 were seen in non-germinal center tumors.
Collapse
Affiliation(s)
- Guilherme Rossi Assis-Mendonça
- School of Medical Sciences, Laboratory of Cancer Genetics, University of Campinas, Campinas, Brazil
- Young Physician Leaders Program, National Academy of Medicine, Rio de Janeiro, Brazil
| | - Letícia Goulart Campos
- School of Medical Sciences, Laboratory of Cancer Genetics, University of Campinas, Campinas, Brazil
| | | | | | | | - Fernando Augusto Soares
- Instituto D'Or de Pesquisa e Ensino (IDOR), Anatomic Pathology D'Or Hospitals Network, São Paulo, Brazil
| | - Cármino Antônio de Souza
- Hematology and Hemotherapy Center, University of Campinas, Campinas, Brazil
- Department of Internal Medicine, School of Medical Sciences, University of Campinas, Campinas, Brazil
| | - José Vassallo
- Instituto D'Or de Pesquisa e Ensino (IDOR), Anatomic Pathology D'Or Hospitals Network, São Paulo, Brazil
- Department of Pathology, School of Medical Sciences, University of Campinas, Campinas, Brazil
| | - Carmen Silvia Passos Lima
- School of Medical Sciences, Laboratory of Cancer Genetics, University of Campinas, Campinas, Brazil
- Department of Anesthesiology, Oncology and Radiology, School of Medical Sciences, University of Campinas, Campinas, Brazil
| |
Collapse
|
2
|
Li XQ, Zhu KW, Lai J, Wu J, Guo XF. Esophageal Ulcer After Intravitreal Ranibizumab Injection in a Patient With Age-Related Macular Degeneration. Gastroenterology Res 2023; 16:118-124. [PMID: 37187551 PMCID: PMC10181341 DOI: 10.14740/gr1603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/02/2023] [Accepted: 03/16/2023] [Indexed: 05/17/2023] Open
Abstract
Ranibizumab is a monoclonal antibody fragment targeted against vascular endothelial growth factor (VEGF) A isoform (VEGF-A). This study aimed to report a case of esophageal ulcer that developed soon after intravitreal ranibizumab injection in a patient with age-related macular degeneration (AMD). A 53-year-old male patient diagnosed with AMD received ranibizumab through intravitreal injection in the left eye. Mild dysphagia occurred 3 days after receiving intravitreal ranibizumab injection for the second time. The dysphagia exacerbated remarkably and was accompanied by hemoptysis 1 day after receiving ranibizumab for the third time. Severe dysphagia accompanied by intense retrosternal pain and pant emerged after injecting ranibizumab for the fourth time. An esophageal ulcer was observed through ultrasound gastroscopy, covered with fibrinous tissue, and surrounded by flushing and congestive mucosae. The patient received proton pump inhibitor (PPI) therapy combined with traditional Chinese medicine (TCM) after discontinuation of ranibizumab. The dysphagia and retrosternal pain were gradually relieved after treatment. Afterwards, the esophageal ulcer has not relapsed since permanent discontinuation of ranibizumab. To our best knowledge, this was the first case of esophageal ulcer related to intravitreal ranibizumab injection. Our study indicated that VEGF-A played a potential role in the development of esophageal ulceration.
Collapse
Affiliation(s)
- Xin Qing Li
- Department of Pharmacy, Ganzhou People’s hospital (The Affiliated Ganzhou Hospital of Nanchang University), Ganzhou 341000, Jiangxi Province, China
- These authors have contributed equally to this article
- Corresponding Author: Xin Qing Li, Department of Pharmacy, Ganzhou People’s hospital (The Affiliated Ganzhou Hospital of Nanchang University), Ganzhou 341000, Jiangxi Province, China.
| | - Ke Wei Zhu
- Office of Pharmacovigilance, Guangzhou Baiyunshan Pharmaceutical Holding Co., Ltd. Baiyunshan Pharmaceutical General Factory, Guangzhou 510515, Guangdong Province, China
- These authors have contributed equally to this article
| | - Jun Lai
- Department of Pharmacy, Ganzhou People’s hospital (The Affiliated Ganzhou Hospital of Nanchang University), Ganzhou 341000, Jiangxi Province, China
| | - Jian Wu
- Department of Pharmacy, Ganzhou People’s hospital (The Affiliated Ganzhou Hospital of Nanchang University), Ganzhou 341000, Jiangxi Province, China
| | - Xiao Fang Guo
- Department of Gastroenterology, Ganzhou People’s hospital (The Affiliated Ganzhou Hospital of Nanchang University), Ganzhou 341000, Jiangxi Province, China
| |
Collapse
|
3
|
Brito ABC, Delamain MT, Fanelli MF, Soares FA, de Souza CA, Vassallo J, Lima CSP. Angiogenesis' related genetic variants alter clinical features and prognosis of diffuse large B-cell lymphoma patients. Tumour Biol 2021; 43:129-140. [PMID: 34219681 DOI: 10.3233/tub-211510] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVES Single nucleotide variants (SNVs) in vascular endothelial growth factor A (VEGFA) and VEGFA receptor (KDR) genes confer different inherited abilities in angiogenesis (AG) pathway. We aimed in the present study to evaluate influence of six VEGFA and four KDR SNVs in clinical features and survival of diffuse large B-cell lymphoma (DLBCL) patients. METHODS One hundred and sixty-eight DLBCL patients diagnosed between June 2009-September 2014 were enrolled in the study. Patients were homogeneously treated with R-CHOP. Genotypes were identified in genomic DNA by real-time polymerase chain reaction. RESULTS Patients with VEGFA -634CC and +936CT or TT genotypes were at increased risk of showing grade III / IV toxicities and not achieving complete remission with treatment, and shorter event-free and overall survival were seen in patients with VEGFA -1154GA or AA genotype and VEGFA ATAGCC haplotype. CONCLUSION Our data suggest that inherited abnormalities in AG's gene modulate clinical features and prognosis of DLBCL patients homogeneously treated with R-CHOP.
Collapse
Affiliation(s)
| | | | | | | | - Cármino Antônio de Souza
- Department of Internal Medicine, Faculty of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.,Haematology and Haemotherapy Centre, University of Campinas, Campinas, São Paulo, Brazil
| | - José Vassallo
- A. C. Camargo Cancer Centre, São Paulo, São Paulo, Brazil.,Laboratory of Molecular and Investigative Pathology, Faculty of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil
| | - Carmen Silvia Passos Lima
- Department of Internal Medicine, Faculty of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil
| |
Collapse
|
4
|
Vasconcelos VCA, Lourenço GJ, Brito ABC, Vasconcelos VL, Maldaun MVC, Tedeschi H, Marie SKN, Shinjo SMO, Lima CSP. Associations ofVEGFAandKDRsingle-nucleotide polymorphisms and increased risk and aggressiveness of high-grade gliomas. Tumour Biol 2019; 41:1010428319872092. [DOI: 10.1177/1010428319872092] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Angiogenesis, induced by the vascular endothelial growth factor A through its ligation to the vascular endothelial growth receptor 2, has been described as a crucial point in high-grade glioma development. The aim of this study was to evaluate the influence of VEGFA–2578C/A, −2489C/T, −1154G/A, −634G/C, and −460C/T, and KDR–604T/C, −271G/A, +1192G/A, and +1719A/T single-nucleotide polymorphisms on risk and clinicopathological aspects of high-grade glioma. This case–control study enrolled 205 high-grade glioma patients and 205 controls. Individuals with VEGFA–2578 CC or CA, VEGFA–1154 GG, VEGFA–634 GC or CC, and VEGFA–460 CT or TT genotypes were under 2.56, 1.53, 1.54, and 1.84 increased risks of high-grade glioma, compared to others, respectively. And 1.61, 2.66, 2.52, 2.53, and 2.02 increased risks of high-grade glioma were seen in individuals with VEGFA–2578 CC plus VEGFA–1154 GG, VEGFA–2578 CC or CA plus VEGFA–634 GC or CC, VEGFA–2578 CC or CA plus VEGFA–460 CT or TT, VEGFA–1154 GG or GA plus VEGFA–634 GC or CC, and VEGFA 634 GC or CC plus VEGFA–460 CT or TT combined genotypes, respectively, when compared to others. The “CAGT” haplotype of KDR single-nucleotide polymorphisms was more common in patients with grade IV than in those with grade III tumors, and individuals carrying this haplotype were at 1.76 increased risk of developing grade IV tumors than others. We present, for the first time, preliminary evidence that VEGFA–2578C/A and VEGFA–1154G/A single-nucleotide polymorphisms increases high-grade glioma risk, and “CAGT” haplotype of the KDR gene alters high-grade glioma aggressiveness and risk of grade IV tumors in Brazil.
Collapse
Affiliation(s)
| | - Gustavo Jacob Lourenço
- Clinical Oncology Service, Department of Internal Medicine, Faculty of Medical Sciences, University of Campinas, Campinas, Brazil
| | - Angelo Borsarelli Carvalho Brito
- Clinical Oncology Service, Department of Internal Medicine, Faculty of Medical Sciences, University of Campinas, Campinas, Brazil
| | - Victor Leal Vasconcelos
- Department of Neurosurgery, Faculty of Medical Sciences, University of Campinas, Campinas, Brazil
| | | | - Helder Tedeschi
- Department of Neurosurgery, Faculty of Medical Sciences, University of Campinas, Campinas, Brazil
| | | | | | - Carmen Silvia Passos Lima
- Clinical Oncology Service, Department of Internal Medicine, Faculty of Medical Sciences, University of Campinas, Campinas, Brazil
| |
Collapse
|
5
|
Aterido A, Julià A, Carreira P, Blanco R, López-Longo JJ, Venegas JJP, Olivé À, Andreu JL, Aguirre-Zamorano MÁ, Vela P, Nolla JM, Marenco-de la Fuente JL, Zea A, Pego JM, Freire M, Díez E, López-Lasanta M, López-Corbeto M, Palau N, Tortosa R, Gelpí JL, Absher D, Myers RM, Fernández-Nebro A, Marsal S. Genome-wide pathway analysis identifies VEGF pathway association with oral ulceration in systemic lupus erythematosus. Arthritis Res Ther 2017; 19:138. [PMID: 28619073 PMCID: PMC5471877 DOI: 10.1186/s13075-017-1345-6] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2017] [Accepted: 05/22/2017] [Indexed: 02/06/2023] Open
Abstract
Background Systemic lupus erythematosus (SLE) is a genetically complex rheumatic disease characterized by heterogeneous clinical manifestations of unknown etiology. Recent studies have suggested the existence of a genetic basis for SLE heterogeneity. The objective of the present study was to identify new genetic variation associated with the clinically relevant phenotypes in SLE. Methods A two-stage pathway-based approach was used to identify the genetic variation associated with the main clinical phenotypes in SLE. In the discovery stage, 482 SLE patients were genotyped using Illumina Human Quad610 microarrays. Association between 798 reference genetic pathways from the Molecular Signatures Database and 11 SLE phenotypes was tested using the set-based method implemented in PLINK software. Pathways significantly associated after multiple test correction were subsequently tested for replication in an independent cohort of 425 SLE patients. Using an in silico approach, we analyzed the functional effects of common SLE therapies on the replicated genetic pathways. The association of known SLE risk variants with the development of the clinical phenotypes was also analyzed. Results In the discovery stage, we found a significant association between the vascular endothelial growth factor (VEGF) pathway and oral ulceration (P value for false discovery rate (PFDR) < 0.05), and between the negative regulation signaling pathway of retinoic acid inducible gene-I/melanoma differentiation associated gene 5 and the production of antinuclear antibodies (PFDR < 0.05). In the replication stage, we validated the association between the VEGF pathway and oral ulceration. Therapies commonly used to treat mucocutaneous phenotypes in SLE were found to strongly influence VEGF pathway gene expression (P = 4.60e-4 to 5.38e-14). Analysis of known SLE risk loci identified a strong association between PTPN22 and the risk of hematologic disorder and with the development of antinuclear antibodies. Conclusions The present study has identified VEGF genetic pathway association with the risk of oral ulceration in SLE. New therapies targeting the VEGF pathway could be more effective in reducing the severity of this phenotype. These findings represent a first step towards the understanding of the genetic basis of phenotype heterogeneity in SLE. Electronic supplementary material The online version of this article (doi:10.1186/s13075-017-1345-6) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Adrià Aterido
- Rheumatology Research Group, Vall d'Hebron Research Institute, Barcelona, 08035, Spain.,Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, 08005, Spain
| | - Antonio Julià
- Rheumatology Research Group, Vall d'Hebron Research Institute, Barcelona, 08035, Spain.
| | - Patricia Carreira
- Rheumatology Department, Hospital Universitario 12 de Octubre, Madrid, 28041, Spain
| | - Ricardo Blanco
- Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Santander, 39008, Spain
| | | | | | - Àlex Olivé
- Rheumatology Department, Hospital Universitari Germans Trias i Pujol, Badalona, 08916, Spain
| | - José Luís Andreu
- Rheumatology Department, Hospital Universitario Puerta de Hierro, Madrid, 28222, Spain
| | | | - Paloma Vela
- Rheumatology Department, Hospital General Universitario de Alicante, Alicante, 03010, Spain
| | - Joan M Nolla
- Rheumatology Department, Hospital Universitari de Bellvitge, Barcelona, 08907, Spain
| | | | - Antonio Zea
- Rheumatology Department, Hospital Universitario Ramón y Cajal, 28034, Madrid, Spain
| | - José María Pego
- Instituto de Investigación Biomédica de Vigo, Ourense y Pontevedra, 36204, Spain
| | - Mercedes Freire
- Rheumatology Department, Hospital Universitario A Coruña, A Coruña, 15006, Spain
| | - Elvira Díez
- Rheumatology Department, Hospital Complejo Asistencial Universitario de León, León, 24001, Spain
| | - María López-Lasanta
- Rheumatology Research Group, Vall d'Hebron Research Institute, Barcelona, 08035, Spain
| | - Mireia López-Corbeto
- Rheumatology Research Group, Vall d'Hebron Research Institute, Barcelona, 08035, Spain
| | - Núria Palau
- Rheumatology Research Group, Vall d'Hebron Research Institute, Barcelona, 08035, Spain
| | - Raül Tortosa
- Rheumatology Research Group, Vall d'Hebron Research Institute, Barcelona, 08035, Spain
| | - Josep Lluís Gelpí
- Life Sciences, Barcelona Supercomputing Centre, Barcelona, 08034, Spain
| | - Devin Absher
- HudsonAlpha Institute for Biotechnology, Huntsville, Alabama, 35806, USA
| | - Richard M Myers
- HudsonAlpha Institute for Biotechnology, Huntsville, Alabama, 35806, USA
| | - Antonio Fernández-Nebro
- Rheumatology Department, Hospital Regional Universitario de Málaga, Málaga, 29010, Spain. .,Instituto de Investigación Biomédica de Málaga, Universidad de Málaga, Málaga, 29010, Spain.
| | - Sara Marsal
- Rheumatology Research Group, Vall d'Hebron Research Institute, Barcelona, 08035, Spain
| |
Collapse
|
6
|
Qin JS, Zheng B, Fu ZF. Buzhong Yiqi Huoxue prescription increases serum VEGF and NO levels in patients with gastric ulcer. Shijie Huaren Xiaohua Zazhi 2014; 22:2758-2762. [DOI: 10.11569/wcjd.v22.i19.2758] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To observe the effect of Buzhong Yiqi Huoxue prescription on serum levels of vascular endothelial growth factor (VEGF) and nitric oxide (NO) in patients with gastric ulcer due to spleen-stomach weakness, and to explore the underlying therapeutic mechanism.
METHODS: Seventy-seven patients with gastric ulcer due to spleen-stomach weakness were randomly divided into two groups to receive Buzhong Yiqi Huoxue prescription (TCM group) and omeprazole (Western medicine group), respectively. The symptoms, gastroscopic results, and serum VEGF and NO levels were compared between the two groups before and after treatment to observe their therapeutic effect on gastric ulcer.
RESULTS: After treatment, the clinical curative effect was better in the TCM group than in the Western medicine group (P < 0.05), and serum levels of VEGF and NO were significantly improved in the TCM group (VEGF: 102.36 ± 12.33 vs 60.85 ± 8.47, P < 0.01; NO: 78.57 ± 8.57 vs 51.87 ± 8.76, P < 0.01) and Western medicine group (VEGF: 102.36 ± 12.33 vs 93.87 ± 9.31, P < 0.01; NO: 78.57 ± 8.57 vs 71.91 ± 8.77, P < 0.01). The improvement was more significant in the TCM group than in the Western medicine group.
CONCLUSION: Buzhong Yiqi Huoxue prescription exerts its therapeutic effects possibly by regulating expression of VEGF and NO in the gastric mucosa of patients with gastric ulcer due to spleen-stomach weakness.
Collapse
|
7
|
Bai LJ, Yang BS. Association between VEGF -634G/C polymorphism and diseases. Shijie Huaren Xiaohua Zazhi 2014; 22:1801-1805. [DOI: 10.11569/wcjd.v22.i13.1801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Vascular endothelial growth factor (VEGF) is a special heparin-binding growth factor, and can significantly stimulate vasculogenesis and angiogenesis in both cancer and healthy tissues. There have been many studies confirming that the single nucleotide polymorphisms (SNP) of VEGF have a close relationship with the occurrence, development, and prognosis of diseases. According to statistics, the human VEGF gene has at least 30 SNP loci, among which VEGF -634C/G, -936C/T and -2578C/A mutations have been proved to regulate the VEGF plasma levels. Here we review the recent advances in understanding the association between VEGF -634G/C polymorphism and diseases.
Collapse
|
8
|
Abstract
PURPOSE OF REVIEW The gastroduodenum has multiple means by which it resists injury from intrinsic and extrinsic factors, including gastric acid, nonsteroidal anti-inflammatory drugs, and Helicobacter pylori. We review recent insights into the mechanisms by which the gastroduodenum resists injury and discuss factors contributing to defensive failure. RECENT FINDINGS Duodenal bicarbonate secretion, a primary defensive mechanism, is mediated by the downregulated in adenoma anion exchanger and is stimulated by estrogens. Nonsteroidal anti-inflammatory drug gastric damage is dependent on toll-like receptor signaling. Portal hypertensive gastropathy impairs extracellular signal-regulated kinase 1/2 phosphorylation, increasing oxidative stress. H. pylori-induced peptic ulcer disease is associated with inadequate regulatory T cell responses. SUMMARY Enhanced understanding of the mechanisms of gastroduodenal defense and injury provides new insight into potential therapeutic targets, which contributes towards the development of more well tolerated and more effective therapies.
Collapse
|
9
|
Abstract
It is well known that Helicobacter pylori infection is associated with many nonmalignant disorders such as gastritis, peptic ulcer, gastroesophageal reflux disease (GERD), gastric polyp, nonsteroidal anti-inflammatory drug (NSAID)/aspirin-induced gastric injury, and functional dyspepsia. In 2008, interesting articles on the association of H. pylori infection with these disorders were presented, some of which intended to reveal the mechanisms of inter-individual differences in response to H. pylori infection, and have demonstrated that genetic differences in host and bacterial factors as well as environmental factors account for these differences. A decline in the occurrence of peptic ulcer related to H. pylori was confirmed. An inverse relationship between H. pylori infection and GERD was also confirmed but the impact of gastric atrophy on the prevention of GERD remained debatable. For NSAID-induced gastric injury, eradication of H. pylori infection has been recommended. During this year, eradication of H. pylori infection was recommended for patients treated with antiplatelet therapy as well as aspirin and NSAID. It was also reported that for patients with functional dyspepsia, eradication of H. pylori offers a modest but significant benefit.
Collapse
Affiliation(s)
- Takahisa Furuta
- Center for Clinical Research, Hamamatsu University School of Medicine, 1-20-1, Handayama, Higashi-Ku, Hamamatsu, Japan.
| | | |
Collapse
|